Clinical trials: Allogeneic Bone Marrow Transplantation
Obstructive Airway Disease
Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCT
The usual treatment for obstructive airway disease (OAD) after allogeneic hematopoietic stem cell transplantation (AHSCT) , which is related to graft versus host disease (GVHD), consists of intensification of systemic…
- Trial name
- Alloforb (NCT00624754)
- Testing
- Formoterol/Budesonide, lactose
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML)
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
The purpose of this study is to learn more about the effects of (classification determinant) CD34+ stem cell selection on graft versus host disease (GVHD) in children, adolescents, and young adults.
- Conditions
- Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML)
- Trial name
- NCT02061800
- Testing
- CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Diane George
Hematological Malignancies
A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors
It is hypothesized that engraftment when administering cyclophosphamide post the stem cell infusion will increase, the incidence of graft versus host disease (GVHD) and day 100 mortality will decrease, and the use of…
- Trial name
- NCT01349101
- Testing
- Total Body Irradiation, Cyclophosphamide, Tacrolimus
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Quality of Life, Patient Reported Outcome (PRO)
Patient-Reported Outcomes in Allogeneic Stem Cell Transplantation and CAR-T Therapy
3.1. Overview Prospective, multicenter, observational cohort study comparing short-term PROs measured with the HM-PRO between two exposure groups: patients undergoing allogeneic stem cell transplantation (allo-SCT) and patients…
- Conditions
- Quality of Life, Patient Reported Outcome (PRO), Allogeneic Blood and Marrow Transplantation (BMT), CAR T Cell Therapy
- Trial name
- QOL-ONE PRO-CT (NCT07289087)
- Volunteers
- 162 people
- Sponsor
- Associazione Qol-one
Severe Aplastic Anemia
Peripheral Blood Allogenic Stem Cell Transplantation Using Non-anti Thymocyte Globulin Regimens in Severe Aplastic Anemia Patients
Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia.The theoretical basis for marrow failure includes primary defects in or damage to the stem cell or the marrow…
- Trial name
- NCT03295058
- Testing
- Non ATG Conditioning regimen, GVHD Prophylaxis, Allogenic Stem Cell Transplantation
- Volunteers
- 50 people
- Sponsor
- Assiut University
Breast Cancer, Chronic Myeloproliferative Disorders
T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict whether patients undergoing donor stem cell transplant will develop acute graft-versus-host disease.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00651716
- Testing
- flow cytometry, laboratory biomarker analysis, Data Collection
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Neutropenia, Sickle Cell Anemia
Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders
OBJECTIVES: I. Determine the efficacy of bone marrow transplantation using matched related donors in patients with nonmalignant hematologic disorders. II.
- Conditions
- Neutropenia, Sickle Cell Anemia, Thalassemia Major, Red-Cell Aplasia, Pure
- Trial name
- NCT00005893
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Sponsor
- Fairview University Medical Center
Allogenic Bone Marrow Transplantation
Evaluation of the Clinical Outcome of Cyclosporine Short Infusion Versus Continuous Infusion Post Allogenic Stem Cell Transplantation
This study focuses on the basis for current immunosuppressive strategies in patients undergoing allogeneic haematopoietic stem cell transplantation at the bone marrow transplantation unit in Ain Shams university hospitals.
- Trial name
- NCT04575779
- Testing
- Cyclosporin with a daily dose of 3 mg/kg/day intravenously over 2 h (short infusion) every 12 h
- Where
- Egypt
- Volunteers
- 31 people
- Sponsor
- Shaymaa Mohammed El-Awady
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
This study will assess the safety, efficacy, and feasibility of ⍺/β CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML)…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT05800210
- Testing
- Miltenyi CliniMACS Prodigy ® system
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Hematologic Malignancies, Nonmalignant Diseases
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Melphalan is a chemotherapy drug used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of melphalan in their bodies and if drug…
- Conditions
- Hematologic Malignancies, Nonmalignant Diseases, Immunodeficiencies, Hemoglobinopathies
- Trial name
- NCT03609827
- Testing
- Melphalan
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, San Francisco
Chronic Myeloid Leukemia
Reduced Intensity AlloSCT in(CML) With Persistent Disease
CML, a malignant disorder of stem cells, is characterized by increases in both immature and mature myeloid, erythroid, and lymphoid cells, as well as platelets in the peripheral blood.
- Trial name
- CML (NCT00531310)
- Testing
- Reduced Intensity Conditioning, Busulfan and Fludarabine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Columbia University
Acute Myeloid Leukaemia, MDS (Myelodysplastic Syndrome)
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
The goal of this clinical trial is to evaluate the effectiveness and safety of the anti-NKG2A monoclonal antibody (Monalizumab) in patients undergoing haploidentical stem cell transplantation (Haplo-SCT) with post-transplantation…
- Conditions
- Acute Myeloid Leukaemia, MDS (Myelodysplastic Syndrome), MPN (Myeloproliferative Neoplasms)
- Trial name
- NCT06892223
- Testing
- Monalizumab (anti-NKG2A monoclonal antibody)
- Where
- 2 sites in Italy
- Volunteers
- 42 people
- Sponsor
- Istituto Clinico Humanitas
Lymphoma, Non-Hodgkin, Leukemia
Allo BMT in Advanced Leukemia or High Grade Lymphoma
To evaluate the role of ablative allogeneic hematopoietic cell transplantation in the treatment of advanced leukemia or lymphoma.
- Conditions
- Lymphoma, Non-Hodgkin, Leukemia, Blood and Marrow Transplant (BMT), Lymphomas: Non-Hodgkin
- Trial name
- NCT00186290
- Testing
- ablative allogeneic hematopoietic cell transplantation
- Where
- United States
- Volunteers
- 145 people
- Sponsor
- Stanford University
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX)
The study will be an open label, single arm, phase I study intended to identify the safety and tolerability of "AML Cell Vaccine" given to eligible MDS RAEB-2 and AML patients who have achieved a best response of complete…
- Trial name
- NCT02493829
- Testing
- AML Cell Vaccine
- Volunteers
- 10 people
- Sponsor
- King's College London
HPV 16 Infection, HPV-Related Carcinoma
Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection
This healthy related donor clinical trial is linked to a recipient clinical trial protocol for therapeutic purposes. In this healthy donor protocol, haploidentical relatives of a patient with recurrent or metastatic human…
- Conditions
- HPV 16 Infection, HPV-Related Carcinoma, Recurrence, Metastatic Cancer
- Trial name
- J21112LINKED (NCT06508138)
- Testing
- pNGVL4a-Sig/E7(detox)/HSP70 plasmid DNA; TA-HPV vaccinia virus
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, L1
Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation
This is a Phase 1, open-label, single center study of short-course oral venetoclax therapy prior to non-myeloablative conditioning with fludarabine and cyclophosphamide in subjects with haematological malignancies who are planned…
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, L1, Leukemia, Lymphoblastic, Acute, L2, Myelodysplastic Syndromes
- Trial name
- VICTORY (NCT05005299)
- Testing
- Venetoclax, Fludarabine, Cyclophosphamide
- Where
- Australia
- Volunteers
- 18 people
- Sponsor
- Melbourne Health
Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
This phase I trial studies the side effects and best dose of CD4+ and CD8+ HA-1 T cell receptor (TCR) (HA-1 T TCR) T cells in treating patients with acute leukemia that persists, has come back (recurrent) or does not respond to…
- Conditions
- Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT03326921
- Testing
- CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and melphalan, before a donor peripheral stem cell transplant or bone marrow transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00453206
- Testing
- allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Wake Forest University Health Sciences
Genetic Disorders, Sickle Cell Anemia
Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis
The purpose of this study is to determine and confirm the role of bone marrow transplantation in the treatment of disorders of the red cell and hemoglobin including sickle cell anemia, thalassemia and diamond blackfan anemia.
- Trial name
- NCT00578435
- Testing
- Busulfan, Cyclophosphamide, BMD
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasms, Lymphoma, Multiple Myeloma
Establishment of a Strategy for Preventing Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation by Exploring Immune Mechanisms of Regulatory and Effector T Cells
The purpose of this study was to explore the regulatory and effector T cell-related immune mechanisms associated with the development of graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT)…
- Trial name
- NCT07150468
- Testing
- sampling blood
- Where
- South Korea
- Volunteers
- 146 people
- Sponsor
- Asan Medical Center